Adagene and Incyte Collaborate on Combination Therapy for Colorectal Cancer

Adagene (ADAG) has partnered with Incyte (INCY) to evaluate a combination therapy for microsatellite stable colorectal cancer (MSS CRC). The Phase 1 trial, set to begin in 2026, will combine Adagene’s muzastotug with Incyte’s INCA33890, targeting patients with limited treatment options. This collaboration expands Adagene’s clinical portfolio and highlights its potential in oncology.

By Maham Fatima Mon, April 20, 2026 at 5:15 PM GMT+3 2 min read · Yahoo Finance · April 20, 2026, 14:15 UTC

Tickers: $ADAG $INCY

Topics: Biotechnology Cancer Research Clinical Trials Pharmaceutical Partnerships

Read the full article at Yahoo Finance

More World news

Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC